RSI společnosti Acelrx Pharmaceuticals Inc
Jaká je hodnota metriky RSI společnosti Acelrx Pharmaceuticals Inc?
Hodnota metriky RSI společnosti Acelrx Pharmaceuticals Inc je 45.25
Jaká je definice metriky RSI?
Index relativní síly (Relative strength index - RSI 14) je technický ukazatel, který se řadí mezi momentum indikátory a měří rychlost a změnu ceny. Jeho hodnota se pohybuje mezi 0 a 100 a používá se k charakterizování překupovaného a přeprodaného stavu.
It is used to identify overbought or oversold conditions in the trading of an asset. It oscillates between 0 and 100 and a stock is considered overbought when the RSI is above 70 and oversold when below 30. The relative strength index (RSI) is typically used on a 14-day timeframe and is calculated according to the formula 100 - [ 100 / (1 + RS)] where RS is the ratio of average gain to average loss. In the calculation of average gain and loss for a certain period, taking the prior value plus the current value is a smoothing technique similar to that used in calculating an exponential moving average. This also means that RSI values become more accurate as the calculation period extends.
Sudden large price movements can create false buy or sell signals in the RSI. The RSI is often used in conjunction with trend lines, as trend line support or resistance often coincides with support or resistance levels in the RSI reading. Watching for divergence between price and the RSI indicator is another means of refining its application. Divergence occurs when a security makes a new high or low in price but the RSI does not make a corresponding new high or low value. Bearish divergence, when price makes a new high but the RSI does not is taken as a sell signal. Bullish divergence that is interpreted as a buy signal occurs when price makes a new low, but the RSI value does not.
RSI společností v sektoru Health Care sektor na NASDAQ ve srovnání se společností Acelrx Pharmaceuticals Inc
Čemu se věnuje společnost Acelrx Pharmaceuticals Inc?
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Firmy s metrikou rsi podobnou společnosti Acelrx Pharmaceuticals Inc
- Hodnota metriky RSI společnosti Baytex je 45.23
- Hodnota metriky RSI společnosti Minco Silver je 45.24
- Hodnota metriky RSI společnosti Alerus Corp je 45.24
- Hodnota metriky RSI společnosti TransAlta Renewables je 45.24
- Hodnota metriky RSI společnosti Cryo-Cell International je 45.24
- Hodnota metriky RSI společnosti NP3 Fastigheter AB (publ) je 45.24
- Hodnota metriky RSI společnosti Acelrx Pharmaceuticals Inc je 45.25
- Hodnota metriky RSI společnosti Clear Blue Technologies International je 45.26
- Hodnota metriky RSI společnosti Geomega Resources je 45.26
- Hodnota metriky RSI společnosti Portman Ridge Finance Corp je 45.26
- Hodnota metriky RSI společnosti Boralex je 45.27
- Hodnota metriky RSI společnosti TUI AG je 45.27
- Hodnota metriky RSI společnosti Insmed Inc je 45.27